What is the approximate price of the original drug of Fezonatant and is it expensive?

As an innovative drug for menopausal vasomotor symptoms in recent years, the price level of Fezolinetant has also become a focus of concern for patients and medical institutions. At present, the original drug of non-zonatant has not been officially launched in China, and domestic patients are temporarily unable to obtain this drug through formal channels. Taking the overseas market as an example, the common specification of the original version of Fezonatant is 45mg*30 tablets, and each box is priced at about more than 600 US dollars, which is equivalent to more than 4,000 yuan in RMB. The price is affected by multiple factors such as international exchange rate fluctuations, sales regional differences and market supply conditions, and the price may change.

From the perspective of price positioning, Fezonatan belongs to the category of high-priced innovative drugs, which is mainly related to its research and development costs, innovation mechanism and market positioning. As a new non-hormonal drug for menopausal hot flashes, fezonatant fills the gap in the treatment of some patients and therefore has strong market demand and clinical value. The high price also reflects the high investment in drug research and development and the exclusive sales rights during the drug patent protection period.

In addition, some generic versions of fezonatant have appeared in overseas markets, such as those produced by Lucius in Laos. This version is basically the same in ingredients as the original drug, but the price is significantly lower than the original product, about more than 900 yuan per box (equivalent to more than 130 U.S. dollars), making it an alternative choice for some patients when their burden is heavy. It should be noted that generic drugs should be certified by relevant regulatory authorities in terms of efficacy and safety, but the quality and regulatory standards of generic drugs may differ in some regions, and patients should carefully consider them when choosing.

Since fezonatant has not yet entered the domestic market, patients who purchase overseas drugs through purchasing agents will have to bear higher economic costs and potential risks, including issues such as drug authenticity, transportation and storage conditions, and subsequent use safety.

Reference materials:https://www.veozah.com/